Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirentelimab extension in eosinophilic gastritis/duodenitis
NCT03664960Phase 2Completed
- Sponsor
- Allakos Inc.
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lirentelimab in eosinophilic gastritis (EG) and eosinophilic duodenitis (EoD), sponsored by Allakos Inc. Primary endpoint: Safety and Tolerability of AK002 by Evaluating Adverse Events Assessed Using the CTCAE Version 4.03 up to 28 months. Started Nov 2018; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic gastritis (EG)eosinophilic duodenitis (EoD)
Beyond the preview
Go deeper on NCT03664960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664960.